Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

Nature

Volumn 432, Issue 7014, 2004, Pages 173-178

  Soutschek, Jürgen ^a   Akinc, Akin ^a   Bramlage, Birgit ^a   Charisse, Klaus ^a   Constien, Rainer ^a   Donoghue, Mary ^a   Elbashir, Sayda ^a   Gelck, Anke ^a   Hadwiger, Philipp ^a   Harborth, Jens ^a   John, Matthias ^a   Kesavan, Venkitasamy ^a   Lavine, Gary ^a   Pandey, Rajendra K ^a   Racie, Timothy ^a   Rajeev, Kallanthottathil S ^a   Röhl, Ingo ^a   Toudjarska, Ivanka ^a   Wang, Gang ^a   Wuschko, Silvio ^a   Bumcrot, David ^a   Kotellansky, Victor ^a   Limmer, Stefan ^a   Manoharan, Muthiah ^a   Vornlocher, Hans Peter ^a   more..

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIODEGRADATION; CHEMICAL MODIFICATION; DISEASES; MONOCLONAL ANTIBODIES; PROTEINS; RNA;

ENDOGENOUS GENES; PLASMA LEVELS; RNA INTERFERENCE (RNAI); THERAPEUTIC SILENCING;

GENES;

APOLIPOPROTEIN B; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA;

RNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC CODE; GENOME ANALYSIS; JEJUNUM MUCOSA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESEARCH; RNA DEGRADATION; RNA INTERFERENCE; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHOLESTEROL; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; INJECTIONS, INTRAVENOUS; JEJUNUM; LIVER; MICE; MICE, TRANSGENIC; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; RNA, MESSENGER; RNA, SMALL INTERFERING; SENSITIVITY AND SPECIFICITY;

ANIMALIA; MUS MUSCULUS;

EID: 9144247189     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03121     Document Type: Article

References (22)

1. Novina, C. D. & Sharp, P. A. The RNAi revolution. Nature 430, 161-164 (2004).
2. Scherr, M., Battmer, K., Dallmann, I., Ganser, A. & Eder, M. Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model. Oligonucleotides 13, 353-363 (2003).
3. Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Med. 9, 347-351 (2003).
4. Reich, S. J. et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210-216 (2003).
5. Zhang, X. et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol Chem. 279, 10677-10684 (2004).
6. Dorn, G. et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49 (2004).
7. Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.-P. & Unverzagt, C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14, 4975-4977 (2004).
8. Burnett, J. R. & Barrett, P. H. Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. Crit. Rev. Clin. Lab. Sci. 39, 89-137 (2002).
9. Farese, R. V. Jr, Ruland, S. L., Flynn, L. M., Stokowski, R. P. & Young, S. G. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc. Natl Acad. Sci. USA 92, 1774-1778 (1995).
10. Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986).
11. Glueck, C. J. et al. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey 1. Metabolism 46, 625-633 (1997).
12. Enjoji, M., Wang, F., Nakamuta, M., Chan, L. & Teng, B. B. Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model. Hum. Gene Ther. 11, 2415-2430 (2000).
13. Linton, M. F. et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92, 3029-3037 (1993).
14. Purcell-Huynh, D. A. et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 95, 2246-2257 (1995).
15. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol. 21, 635-637 (2003).
16. Bridge, A. J., Pebernard, S., Ducraux, A., Nicoulaz, A.-L. & Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nature Genet. 34, 263-264 (2003).
17. Llave, C., Xie, Z., Kasschau, K. D. & Carrington, J. C. Cleavage of Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 20, 2053-2056 (2002).
18. Yekta, S., Shih, I. H. & Bartel, D. P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594-596 (2004).
19. Damha, M. J. & Ogilvie, K. K. Oligoribonucleotide synthesis. The silyl-phosphoramidite method. Methods Mol. Biol. 20, 81-114 (1993).
20. Iyer, R. P., Egan, W., Regan, J. B. & Beaucage, S. L. 3H-1,2-benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid phase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112, 1253-1254 (1990).
21. Zlot, C. H. et al. Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. J. Lipid Res. 40, 76-84 (1999).
22. Hammad, S. M. et al. Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Metabolism 52, 916-921 (2003).